Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics Inc. has demonstrated a commitment to advancing its clinical programs through modestly increasing total operating expenses aligned with its strategic initiatives, particularly in supportive oncology and metabolic disease. Notably, over 65% of participants in its clinical trials reported reductions in pain and pruritus, indicating positive outcomes and potential market viability for its therapies. Furthermore, the company has reinforced its growth potential through strengthened collaborations in academia, clinical settings, and artificial intelligence, while maintaining disciplined expense management as it progresses its lead asset HT-001.

Hoth Therapeutics Inc. reported a net loss of approximately $4.11 million for the recent quarter, translating to a loss of $(0.30) per share. For the second quarter of 2025, the company recorded no revenue, which is in line with expectations, and total operating expenses decreased to $2.2 million from $3.4 million in the previous quarter. However, the continued absence of revenue combined with substantial net losses raises concerns about the company's financial sustainability and ability to fund ongoing development efforts.